Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
- Industry News
- Technology
- Software
- Banking
- Automotive
- Energy
- More
- Drug Approvals
- Clinical Trial Calendar

Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard

Crypto
Cryptocurrency
Blockchain

Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies

Politics
US
World
White House
Elections
General News

Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard

Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health

Slide Shows

Entertainment
Top Stories
- Pop
- Rock
- Classic Rock
- Rap/Hip-Hop
- Country
- Alternative
- Oldies
- All Genre

Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services

Premium
Intelligent Investor
Biotech Investor NEW
Login

Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us

Business
Corp. News
- Latest Headlines
- Biotech
- Investors
- Stock Alerts
- IPOs
- M&A
Industry News
- Technology
- Software
- Banking
- Automotive
- Energy
- More
Corp. Calendars
Earnings Calendar
FDA Calendars
- Drug Approvals
- Clinical Trial Calendar
Ratings Changes
Economy
- US
- Europe
- Asia
- Global
- Economic Calendar
- Economic Scorecard
Crypto
- Cryptocurrency
- Blockchain
Markets
Market News
Politics
- US
- World
- White House
- Elections
- General News
Forex
Health
Health News
Slide Shows
Entertainment
Entertainment News
- Top Stories
Music News
- Pop
- Rock
- Classic Rock
- Rap/Hip-Hop
- Country
- Alternative
- Oldies
- All Genre
Content Licensing
Premium
More

Abbvie (ABBV)

AbbVie Submits FDA Application For RINVOQ In Severe Alopecia Areata Based On Phase 3 Data 4/28/2026 8:13:26 AM

AbbVie Says Rinvoq Tops Humira In Rheumatoid Arthritis Study 4/28/2026 7:35:05 AM

AbbVie : RINVOQ Outperforms HUMIRA In Head-to-Head Rheumatoid Arthritis Study 4/28/2026 7:04:05 AM

AbbVie Seeks FDA Nod For SKYRIZI Subcutaneous Induction In Crohn's Disease 4/27/2026 8:32:06 AM

AbbVie Submits Regulatory Application To FDA For SKYRIZI SC Induction For Adults With Active Crohn's Disease 4/27/2026 8:09:25 AM

Weekly Buzz: SNY, REGN Get FDA Nod; It's A No For ABBV, GRCE; LLY Acquires Kelonia 4/24/2026 10:34:13 AM

AbbVie: FDA Issues CRL For TrenibotulinumtoxinE Related To Manufacturing Processes 4/24/2026 1:20:25 AM

AbbVie Receives FDA Complete Response Letter For TrenibotE Biologics License Application 4/23/2026 9:51:49 PM

AbbVie Announces Founding Sponsorship Of BioLabs University Of Toronto 4/21/2026 12:19:13 AM

AbbVie Expands Partnership With BioLabs As Founding Sponsor Of New University Of Toronto Hub 4/20/2026 10:08:10 PM

Nxera Pharma To Receive $10 Mln Milestone Payment From AbbVie Under Neurology Collaboration 4/20/2026 2:53:44 AM

Nxera Pharma Reaches Third R&D Milestone In AbbVie Collaboration, Secures $10 Mln Payment 4/20/2026 2:35:40 AM

Haisco Reaches Deal With AbbVie To Develop Novel Medicines For Pain 4/13/2026 2:37:03 AM

AbbVie's Phase 2 Trial Shows 62.7% Response With Mirvetuximab In Platinum-Sensitive Ovarian Cancer 4/12/2026 10:45:15 AM

Allergan Aesthetics Highlights TrenibotE Safety And Medical Weight Loss Insights At AAD 2026 3/30/2026 8:05:06 AM

AbbVie To Showcase New Clinical And Real-World Evidence In Immune-Mediated Skin Diseases At 2026 AAD 3/27/2026 10:03:06 AM

Allergan Aesthetics To Unveil Next Evolution Of AA Signature At AMWC 2026 3/19/2026 3:04:45 AM

AbbVie Reports Positive Topline Results In Phase 1 Study For ABBV-295 In Weight Management 3/9/2026 8:24:42 AM

AbbVie Reports Positive Phase 1 Results For ABBV-295, Long-Acting Amylin Analog In Weight Management 3/9/2026 8:05:22 AM

AbbVie Reports Positive Phase 3 Results For Risankizumab In Crohn's Disease 3/2/2026 9:20:01 AM

- 1
- 2
- Next »

Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us | Contact Us | Privacy | Sitemap